- Home
- EDU vs ROIV Comparison
EDU vs ROIV Comparison
Compare EDU & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDU | ROIV |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 14.1B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | EDU | ROIV |
|---|---|---|
| Price | $56.42 | $22.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $57.87 | $24.31 |
| AVG Volume (30 Days) | 635.8K | ★ 6.2M |
| Earning Date | 01-28-2026 | 02-09-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.27 | N/A |
| Revenue | ★ $4,987,826,000.00 | $20,329,000.00 |
| Revenue This Year | $10.87 | N/A |
| Revenue Next Year | $10.36 | $741.42 |
| P/E Ratio | $24.24 | ★ N/A |
| Revenue Growth | ★ 7.29 | N/A |
| 52 Week Low | $40.66 | $8.73 |
| 52 Week High | $61.56 | $23.91 |
Technical Indicators
Market Signals| Indicator | EDU | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 52.11 | 57.86 |
| Support Level | $53.80 | $22.15 |
| Resistance Level | $60.06 | $23.20 |
| Average True Range (ATR) | 1.36 | 0.74 |
| MACD | -0.34 | 0.01 |
| Stochastic Oscillator | 41.53 | 67.24 |
Price Performance
Historical ComparisonAbout EDU New Oriental Education & Technology Group Inc.
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.